Engstrom P F, Benson A B, Cohen A, Doroshow J, Kiel K, Niederhuber J, Roh M, Tempero M
Fox Chase Cancer Center, Temple University Medical School, Philadelphia, Pennsylvania, USA.
Oncology (Williston Park). 1996 Nov;10(11 Suppl):140-75.
In summary, the committee believes that a multidisciplinary approach is necessary for the management of the patient with colorectal cancer. The committee endorses the concept that treatment of patients on a clinical trial has priority over standard or accepted therapy. The recommended surgical procedure for managing resectable colon cancer is an en bloc resection; laparoscopic surgery should be done only in the context of a clinical trial. For patients with stage III disease, 5-FU-based adjuvant chemotherapy is recommended. A patient who has metastatic disease in the liver or lung should be considered for surgical resection if he or she is a candidate for surgery and if surgery can extend survival. The committee advocates a conservative post-treatment surveillance program for colon and rectal cancer patients. A determination of CEA should be done only if CEA was elevated at baseline and decreased following primary resection. Abdominal and pelvic CT scans should be utilized only when there are clinical indications of possible recurrence. Patients whose disease progresses during 5-FU-based therapy should be considered for treatment with irinotecan or encouraged to participate in a phase I or II clinical trial.
总之,委员会认为,结直肠癌患者的管理需要多学科方法。委员会认可这样的理念,即参与临床试验的患者治疗优先于标准或公认疗法。推荐用于治疗可切除结肠癌的手术方法是整块切除;腹腔镜手术仅应在临床试验背景下进行。对于Ⅲ期疾病患者,推荐基于5-氟尿嘧啶的辅助化疗。如果肝或肺有转移性疾病的患者是手术候选者且手术可延长生存期,则应考虑手术切除。委员会主张对结肠癌和直肠癌患者采取保守的治疗后监测方案。仅当基线时癌胚抗原(CEA)升高且初次切除后降低时才应测定CEA。仅当有临床迹象提示可能复发时才应使用腹部和盆腔CT扫描。在基于5-氟尿嘧啶的治疗期间疾病进展的患者应考虑用伊立替康治疗或鼓励其参与Ⅰ期或Ⅱ期临床试验。